GLIOBLASTOMA (GBM) TREATMENT:
OPTIONS AND ADVANCED APPROACHES
GBM remains one of oncology's hardest challenges โ but advanced approaches including BNCT, TTFields, immunotherapy, and clinical trials in Asia are expanding what is possible for newly diagnosed and recurrent patients.
analyticsAt a Glance
- check_circleStandard Stupp protocol: surgery + temozolomide + RT โ median OS 14โ16 months
- check_circleBNCT in Japan and China showing improved survival in Phase I/II GBM trials
- check_circleTTFields (Optune) approved by FDA โ adds 3โ5 months median OS when combined with TMZ
- check_circleMultiple GBM immunotherapy trials accessible in China and India through CancerFax
What Is Glioblastoma (GBM)?
Glioblastoma multiforme (GBM), classified as WHO Grade 4 IDH-wildtype glioma, is the most common and most aggressive primary brain tumour in adults โ comprising approximately 15% of all brain tumours and almost 50% of malignant brain tumours.
โGBM is not one disease โ it is a collection of molecularly distinct tumours that look similar under a microscope but respond differently to treatment. Molecular profiling changes everything.โ
Molecular Subtypes That Matter
MGMT promoter methylation status (predicts temozolomide benefit), IDH mutation (defines lower-grade vs GBM), EGFR amplification, PTEN loss, and TERT promoter mutations are the key biomarkers guiding treatment decisions and clinical trial eligibility in GBM.
Why GBM Is Difficult to Treat
GBM grows diffusely into normal brain โ no surgical margin is possible. The blood-brain barrier limits drug delivery. Tumour heterogeneity means subclones resist targeted therapies. Immunosuppressive tumour microenvironment blunts immune responses.
The Stupp Protocol: Standard of Care
The Stupp protocol (2005) established concurrent temozolomide + radiotherapy followed by adjuvant TMZ as the standard first-line treatment for newly diagnosed GBM โ improving median OS from 12 months (RT alone) to 14โ16 months.
Protocol Steps
Maximal safe resection (or biopsy if eloquent location) โ concurrent TMZ (75 mg/mยฒ daily) + RT (60 Gy in 30 fractions) ร 6 weeks โ 4 weeks rest โ adjuvant TMZ (150โ200 mg/mยฒ, days 1โ5, 28-day cycles ร 6 cycles). PCP prophylaxis throughout.
MGMT Methylation and TMZ Benefit
MGMT promoter methylation silences the DNA repair enzyme that reverses TMZ's cytotoxic effect. MGMT-methylated GBM patients derive the most benefit from TMZ โ achieving median OS of 21โ23 months vs 12โ14 months in unmethylated patients. MGMT testing is mandatory before treatment.
Advanced and Emerging Treatment Options for GBM
Beyond the Stupp protocol, multiple advanced modalities are available through clinical trials or as approved therapies โ particularly accessible through CancerFax's network in Asia.
| Treatment | Mechanism | Evidence Status | Access |
|---|---|---|---|
| Tumour Treating Fields (TTFields / Optune) | Low-intensity alternating electric fields disrupt mitosis in dividing cancer cells | FDA-approved: adds 3โ5 months median OS vs TMZ alone (EF-14 trial) | USA, Europe; devices available in India; increasing availability |
| BNCT | Boron-10 neutron capture โ intracellular nuclear reaction in boron-loaded GBM cells | Phase I/II: improved OS vs historical Stupp in some series; Phase III ongoing in Japan/China | Japan, China (Xiamen, Beijing); CancerFax coordinates access |
| Anti-PD-1 immunotherapy (nivolumab, pembrolizumab) | Checkpoint blockade โ restores T-cell anti-tumour activity | Phase III (Checkmate 143, KEYNOTE-028): negative for unselected GBM; ongoing for subgroups | Available broadly; efficacy limited to MSI-H / hypermutated subsets |
| CAR-T cell therapy (GBM-targeted) | Engineered T-cells targeting EGFRvIII, IL13Rฮฑ2, GD2 | Phase I/II: responses in some patients; intratumoral delivery showing promise | Clinical trials in China (CancerFax trial matching) and USA |
| Oncolytic virus therapy (CG0070, Delta-24-RGD) | Engineered viruses selectively replicate in and lyse tumour cells | Phase I/II: intratumoral delivery; promising safety profile; China has active programme | China clinical trials; CancerFax can assess eligibility |
| Bevacizumab (anti-VEGF) | Anti-angiogenic โ reduces tumour vasculature | FDA-approved for recurrent GBM; modest PFS benefit, no OS benefit in first-line | Broadly available in India and China |
| Tumour vaccines (DCVax-L, neoantigen vaccines) | Patient-specific dendritic cell or neoantigen vaccines to activate anti-GBM immunity | DCVax-L Phase III: improved OS in MGMT-methylated subset; emerging neoantigen programmes | DCVax-L approved in Germany; neoantigen trials in US, China |
GBM Outcomes: Key Numbers
- 14โ16 moMedian OS โ Stupp ProtocolStandard temozolomide + RT for newly diagnosed GBM
- 21โ23 moMedian OS โ MGMT-Methylated GBM + TMZBest outcomes with standard treatment in methylated patients
- +3โ5 moTTFields OS Benefit (EF-14 trial)Added when combined with maintenance temozolomide
- 5โ10%5-Year SurvivalAcross all GBM patients; higher in IDH-mutant, MGMT-methylated subsets
Recurrent GBM: What Are the Options?
GBM almost universally recurs โ typically within 6โ9 months of completing initial chemoradiation. The recurrent setting is where clinical trial access and advanced modalities have the greatest potential impact.
Re-Resection
Re-surgery for recurrent GBM is considered when the recurrent tumour is resectable, patient has good performance status, and the interval from first resection is โฅ6 months. OS benefit is modest but quality of life improves with symptom relief and steroid dose reduction.
Stereotactic Re-Irradiation (SRS/SBRT)
SRS or SBRT to the recurrent lesion achieves local control in 50โ70% of patients with small-volume recurrence and adequate separation from prior RT field. Particularly valuable when re-resection is not feasible due to eloquent cortex involvement.
BNCT for Recurrent GBM
BNCT is particularly promising for recurrent GBM because the boron carrier (BPA) accumulates in metabolically active tumour cells โ including infiltrating cells beyond MRI-visible lesions. Phase II Japanese data shows median OS of ~15 months post-BNCT in recurrent patients, substantially exceeding historical controls.
Clinical Trials
Recurrent GBM is the most active area for investigational trials โ oncolytic viruses, neoantigen vaccines, novel CAR-T constructs, and combination immunotherapy. China and India have active protocols enrolling international patients. CancerFax performs clinical trial matching for recurrent GBM cases.
Advanced GBM Approaches: Benefits and Considerations
Understanding what each advanced approach can realistically offer helps patients and families make informed, values-aligned decisions.
Potential Benefits
- BNCT: improved OS in recurrent GBM Phase II dataJapanese series show median OS exceeding historical Stupp outcomes in recurrent disease
- TTFields: FDA-approved OS benefitThe only device-based therapy with Phase III evidence in GBM โ modest but real benefit
- Clinical trials: access to investigational agentsPhase I/II trials may provide access to promising agents years before regulatory approval
- CAR-T and oncolytic viruses: mechanistically promisingPhase I signals of response in select patients โ most active development area in GBM
Realistic Considerations
- No curative treatment exists for GBMAll current approaches are life-extending, not curative โ honest prognosis discussion is essential
- TTFields requires 18+ hours/day device wearCompliance affects benefit; quality of life impact of device wear must be weighed
- Clinical trial eligibility is not guaranteedSpecific molecular requirements and performance status criteria must be met
- Travel for BNCT requires planningBNCT in Japan or China requires on-site attendance โ CancerFax coordinates logistics for international patients
Related Resources
Further reading on advanced radiation and brain tumour treatment options.
Frequently Asked Questions
Glioblastoma Treatment
Should MGMT methylation testing always be done before starting GBM treatment?
Yes โ MGMT promoter methylation testing should always be performed on newly diagnosed GBM biopsy specimens before starting treatment. MGMT methylation status is the single strongest predictive biomarker for temozolomide benefit: methylated patients achieve significantly longer OS with TMZ and should receive full Stupp protocol. Unmethylated patients have less TMZ benefit and may be better candidates for clinical trials of alternative approaches (TTFields, immunotherapy, BNCT) from the outset.
Is BNCT better than standard radiotherapy for GBM?
Phase I/II data from Japan suggest BNCT achieves median OS outcomes that compare favourably to the Stupp protocol โ with some series reporting median OS of 23+ months for newly diagnosed GBM, and 15+ months for recurrent GBM. However, BNCT has not been tested against the Stupp protocol in a randomised Phase III trial for GBM. Phase III trials are now underway in Japan and China. Until Phase III data matures, BNCT for GBM remains an advanced option best accessed through clinical trial participation.
What is the role of immunotherapy in GBM?
Despite significant interest, anti-PD-1 checkpoint inhibitors have not demonstrated survival benefit in unselected GBM in Phase III trials (Checkmate 143, KEYNOTE-028). Exceptions include the rare GBM subset with microsatellite instability (MSI-H) or hypermutation, where PD-1 inhibitors show activity. Research continues into combination approaches (checkpoint inhibitors + radiation, + tumour vaccines) and into tumour microenvironment modulation. Clinical trial participation remains the best route to immunotherapy access for most GBM patients.
Can GBM patients access clinical trials in China or India?
Yes. Multiple GBM clinical trials are active in China, including oncolytic virus studies, CAR-T trials targeting EGFRvIII and GD2, BNCT protocols, and neoantigen vaccine studies. India has active GBM clinical trial programmes at Tata Memorial and AIIMS. CancerFax performs systematic clinical trial matching for GBM patients โ identifying open trials based on molecular profile (MGMT, IDH, EGFR), prior treatment history, and performance status, and coordinating the eligibility screening process.
How is treatment different for elderly patients or those with poor performance status?
For elderly patients (>70 years) or those with ECOG PS 2+, modified protocols are used: hypofractionated radiotherapy (40 Gy in 15 fractions or 25 Gy in 5 fractions) ยฑ temozolomide, based on MGMT status. The Nordic trial and CCTG CE.6 trial established that for elderly patients, temozolomide alone is non-inferior to RT in MGMT-methylated patients. Performance status-adjusted protocols are available at experienced centres in India and China at lower cost than in the West.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Facing a GBM Diagnosis? Explore Your Options.
Upload your MRI, pathology (MGMT, IDH, EGFR), and treatment history. Our neuro-oncology team will review your case, identify clinical trial eligibility, and outline advanced options in China or India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.